News about "AVTOZMA IV "

Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market

Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market

AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).

AVTOZMA IV | 03/10/2025 | By Dineshwori


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members